The toxins could potentially be used as ‘markers’ for doctors to identify Parkinson’s patients at a higher risk of developing ...
Australian-founded medical technology company SYMBYX today announced compelling results from a 72-week randomized controlled ...
This landmark trial is the largest-to-date and was only made possible because of the seminal work of Australian scientists from the ...
ADAS-Cog13 difference −12.78 (P < 0.0001) with oral blarcamesine treatment compared to ADNI control group at Week 144 77.4 ...
Introduction Although there are some drugs to control Parkinson’s disease (PD), they have several side effects and cannot ...